Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
CVXL-0107 a glutamate release inhibitor, has shown evidence of antiparkinsonian and
antidyskinetic activity in a macaque model and has shown a significant effect on the
UPDRS-III (Movement Disorder Society - Unified Parkinson's Disease Rating Scale) while "ON",
as well as an increase of "ON-time" without dyskinesia or without troublesome dyskinesia in a
previous phase 2a proof of concept study. This study will confirm the efficacy of CVXL-0107
in combination with optimal dose of levodopa on motor symptoms of Parkinson's disease (PD) .